554 related articles for article (PubMed ID: 23466709)
1. Saccharomyces boulardii does not prevent relapse of Crohn's disease.
Bourreille A; Cadiot G; Le Dreau G; Laharie D; Beaugerie L; Dupas JL; Marteau P; Rampal P; Moyse D; Saleh A; Le Guern ME; Galmiche JP;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):982-7. PubMed ID: 23466709
[TBL] [Abstract][Full Text] [Related]
2. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study.
Naftali T; Bar-Lev Schleider L; Dotan I; Lansky EP; Sklerovsky Benjaminov F; Konikoff FM
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1276-1280.e1. PubMed ID: 23648372
[TBL] [Abstract][Full Text] [Related]
3. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.
Fedorak RN; Feagan BG; Hotte N; Leddin D; Dieleman LA; Petrunia DM; Enns R; Bitton A; Chiba N; Paré P; Rostom A; Marshall J; Depew W; Bernstein CN; Panaccione R; Aumais G; Steinhart AH; Cockeram A; Bailey RJ; Gionchetti P; Wong C; Madsen K
Clin Gastroenterol Hepatol; 2015 May; 13(5):928-35.e2. PubMed ID: 25460016
[TBL] [Abstract][Full Text] [Related]
4. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
Panés J; López-Sanromán A; Bermejo F; García-Sánchez V; Esteve M; Torres Y; Domènech E; Piqueras M; Gomez-García M; Gutiérrez A; Taxonera C; Sans M;
Gastroenterology; 2013 Oct; 145(4):766-74.e1. PubMed ID: 23770132
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
[TBL] [Abstract][Full Text] [Related]
6. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission.
Garcia Vilela E; De Lourdes De Abreu Ferrari M; Oswaldo Da Gama Torres H; Guerra Pinto A; Carolina Carneiro Aguirre A; Paiva Martins F; Marcos Andrade Goulart E; Sales Da Cunha A
Scand J Gastroenterol; 2008; 43(7):842-8. PubMed ID: 18584523
[TBL] [Abstract][Full Text] [Related]
7. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
[TBL] [Abstract][Full Text] [Related]
8. Sargramostim for active Crohn's disease.
Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
[TBL] [Abstract][Full Text] [Related]
9. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
Hanauer S; Sandborn WJ; Persson A; Persson T
Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].
Gong JF; Niu LY; Wei XW; Zhu WM; Li N; Li JS
Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(16):1213-7. PubMed ID: 19781164
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
13. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
Winter TA; Wright J; Ghosh S; Jahnsen J; Innes A; Round P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1337-46. PubMed ID: 15606396
[TBL] [Abstract][Full Text] [Related]
14. Changes in the Crohn's Disease Activity Index and Safety of Administering
Oh GM; Moon W; Seo KI; Jung K; Kim JH; Kim SE; Park MI; Park SJ
Korean J Gastroenterol; 2020 Dec; 76(6):314-321. PubMed ID: 33250507
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
Cindoruk M; Erkan G; Karakan T; Dursun A; Unal S
Helicobacter; 2007 Aug; 12(4):309-16. PubMed ID: 17669103
[TBL] [Abstract][Full Text] [Related]
17. Lactobacillus GG in inducing and maintaining remission of Crohn's disease.
Schultz M; Timmer A; Herfarth HH; Sartor RB; Vanderhoof JA; Rath HC
BMC Gastroenterol; 2004 Mar; 4():5. PubMed ID: 15113451
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
[TBL] [Abstract][Full Text] [Related]
19. Probiotics for maintenance of remission in Crohn's disease.
Rolfe VE; Fortun PJ; Hawkey CJ; Bath-Hextall F
Cochrane Database Syst Rev; 2006 Oct; (4):CD004826. PubMed ID: 17054217
[TBL] [Abstract][Full Text] [Related]
20. Saccharomyces boulardii in maintenance treatment of Crohn's disease.
Guslandi M; Mezzi G; Sorghi M; Testoni PA
Dig Dis Sci; 2000 Jul; 45(7):1462-4. PubMed ID: 10961730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
